Newsbenzinga
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
· Published
Article summary
Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.
An excerpt from the original article.
Comments —
Loading comments…